This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
ELV vs. PGNY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Cigna (CI) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Cigna's (CI) stock price is increasing on the back of solid performances in the Evernorth and Cigna Healthcare businesses.
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
Humana (HUM) Rises 23% in Past 6 Months: More Room to Run?
by Zacks Equity Research
Humana (HUM) is well-poised for growth on improving revenues, numerous contract wins and adequate cash-generating abilities.
Acadia (ACHC) Reveals its Long-Term Goals: What You Should Know
by Zacks Equity Research
From 2022 to 2028, Acadia Healthcare (ACHC) expects to see a 9-11% CAGR in revenues.
The Joint (JYNT) Expands Operations to Alaska With 3 Clinics
by Zacks Equity Research
The Joint's (JYNT) expansionary move is expected to be a prudent one, given the growing demand for affordable and convenient chiropractic care in the region.
Cigna (CI) Focuses on Enhancing Pharmacy Offerings in 2023
by Zacks Equity Research
Cigna (CI) decides to integrate cost-effective biosimilars within its commercial formularies from next year in a bid to drive pharmacy revenues.
Centene (CNC) Concludes Magellan Rx Divestment to Prime
by Zacks Equity Research
Centene (CNC) completes Magellan Rx divestment within the scheduled time.
The Zacks Analyst Blog Highlights Apple, IBM, Elevance Health, Charter Communications and Archer-Daniels-Midland Company
by Zacks Equity Research
Apple, IBM, Elevance Health, Charter Communications and Archer-Daniels-Midland Company are included in this Analyst Blog.
Top Stock Reports for Apple, IBM & Elevance Health
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), International Business Machines Corporation (IBM) and Elevance Health Inc. (ELV).
NextGen (NXGN) Buys TSI Healthcare to Boost Ambulatory Services
by Zacks Equity Research
NextGen (NXGN) acquires TSI Healthcare which may further solidify NXGN's position in the ambulatory healthcare space.
Humana (HUM) Ups '23 Medicare Advantage Membership Growth View
by Zacks Equity Research
Humana (HUM) expects 2023 net membership gains to be a minimum of 10.9% from the 2022 projection.
Why You Should Retain Centene (CNC) in Your Portfolio Now
by Zacks Equity Research
Divesting operations like PANTHERx, Magellan Specialty Health and others are going to enable Centene (CNC) to intensify its focus on its core Managed Care business.
Patterson Companies (PDCO) Q2 Earnings Beat, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter 2023 results reflect unfavorable currency movements.
Acadia (ACHC) JV Opens New Behavioral Health Unit in Fort Wayne
by Zacks Equity Research
The opening of the new hospital is in line with Acadia Healthcare's (ACHC) vision to bolster its reach in the U.S. behavioral healthcare market.
3 Top-Ranked Large-Caps With Big Growth
by Derek Lewis
Large-cap stocks are a staple in every portfolio. They're well-established, have greater analyst coverage, typically pay dividends, and help shield investors from volatility.
What You Need to Know From UnitedHealth's (UNH) Latest Outlook
by Zacks Equity Research
UnitedHealth (UNH) expects the top line to be within the range of $357-$360 billion in 2023.
Factors That Make Elevance Health (ELV) a Lucrative Bet Now
by Zacks Equity Research
Elevance Health (ELV) continues to benefit from sustained top-line growth, higher membership in Government business and a sturdy financial position.
ELV vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ELV vs. PGNY: Which Stock Is the Better Value Option?
Cigna (CI) Rises 18.9% in 6 Months: More Growth in Store?
by Zacks Equity Research
Cigna (CI) expects its long-term adjusted earnings per share to witness 10-13% average annual growth.
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
Why You Should Add UnitedHealth (UNH) to Your Portfolio Now
by Zacks Equity Research
The improvement of the economy is likely to support UnitedHealth's (UNH) commercial business recovery.
Centene (CNC) to Sell Magellan Arm, To Use Proceeds for Buybacks
by Zacks Equity Research
Centene (CNC) strikes a deal with Evolent to divest Magellan Specialty Health, a Magellan Health arm, to deepen focus on solidifying its core Managed Care business.